Zobrazeno 1 - 10
of 179
pro vyhledávání: '"Garbayo, E."'
Publikováno v:
In Journal of Controlled Release 28 December 2015 220 Part A:388-396
Publikováno v:
In Journal of Controlled Release 10 April 2015 203:23-38
Biodegradation and heart retention of polymeric microparticles in a rat model of myocardial ischemia
Autor:
Formiga, F.R., Garbayo, E., Díaz-Herráez, P., Abizanda, G., Simón-Yarza, T., Tamayo, E., Prósper, F., Blanco-Prieto, M.J.
Publikováno v:
In European Journal of Pharmaceutics and Biopharmaceutics November 2013 85(3) Part A:665-672
Autor:
Díaz-Herráez, P., Garbayo, E., Simón-Yarza, T., Formiga, F.R., Prosper, F., Blanco-Prieto, M.J.
Publikováno v:
In European Journal of Pharmaceutics and Biopharmaceutics September 2013 85(1):143-150
Therapeutical management of Parkinson's disease (PD) is predominantly focused on controlling motor symptoms and there is no gold standard treatment strategy. Consequently, the medical treatment is tailored to each patient, based on the severity of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1111::fb7345d61863e059be5a5bb86a520319
https://hdl.handle.net/10171/63294
https://hdl.handle.net/10171/63294
Autor:
Pascual-Gil, S.1,2, Garbayo, E.1,2, Blanco-Prieto, M. J.1,2, Abizanda, G.2,3, Iglesias, E.2,3, Prósper, F.2,3
Publikováno v:
Journal of Drug Targeting. Jun-Jul2019, Vol. 27 Issue 5/6, p573-581. 9p.
Publikováno v:
In Measurement 2011 44(5):906-916
Autor:
Garbayo, E., Montero-Menei, C.N., Ansorena, E., Lanciego, J.L., Aymerich, M.S., Blanco-Prieto, M.J.
Publikováno v:
In Journal of Controlled Release 2009 135(2):119-126
Autor:
Torres-Ortega, P.V. (Pablo Vicente), Smerdou, C. (Cristian), Ansorena-Artieda, E. (Eduardo), Ballesteros-Briones, M.C. (María Cristina), Martisova, E. (Eva), Garbayo, E. (Elisa), Blanco-Prieto, M.J. (María José)
Publikováno v:
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
instname
Human glial cell line-derived neurotrophic factor (hGDNF) is the most potent dopaminergic factor described so far, and it is therefore considered a promising drug for Parkinson’s disease (PD) treatment. However, the production of therapeutic protei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::24232c1b251e4443825f4b4a333e4885
https://hdl.handle.net/10171/63698
https://hdl.handle.net/10171/63698
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.